MUMBAI, India, April 17 -- Intellectual Property India has published a patent application (202611022899 A) filed by Panipat Institute Of Engineering And Technology, Samalkha, Haryana, on Feb. 26, for 'enzyme-triggered self-immolative prodrug system for targeted and controlled chemotherapy.'
Inventor(s) include Prof. Daisy Arora; Prof. Parveen Kumar Goyal; Dr. Arti Soni; and Sakshi Garg.
The application for the patent was published on April 17, under issue no. 16/2026.
According to the abstract released by the Intellectual Property India: "An enzyme-triggered self-immolative prodrug system for targeted chemotherapy is disclosed, comprising a therapeutic agent, a self-immolative linker, and an enzyme-cleavable triggering moiety. The prodrug system remains substantially stable under physiological conditions during systemic circulation and undergoes selective activation in the presence of disease-associated enzymes overexpressed in tumor or pathological microenvironments. Enzymatic cleavage of the triggering moiety initiates a self-immolative cascade resulting in controlled and complete release of the active chemotherapeutic agent at the target site. The invention enhances tumor selectivity, reduces systemic toxicity, and improves therapeutic efficacy, providing a versatile and adaptable platform for targeted cancer therapy."
Disclaimer: Curated by HT Syndication.
